BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $415
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $389 to $415.
November 07, 2023 | 5:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on Vertex Pharmaceuticals and raises the price target from $389 to $415.
The raised price target by BMO Capital indicates a positive outlook for Vertex Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100